Co-occurring diagnoses among FMR1 premutation allele carriers
Article first published online: 6 JAN 2010
© 2010 John Wiley & Sons A/S
Volume 77, Issue 4, pages 374–381, April 2010
How to Cite
Hunter, J., Rohr, J. and Sherman, S. (2010), Co-occurring diagnoses among FMR1 premutation allele carriers. Clinical Genetics, 77: 374–381. doi: 10.1111/j.1399-0004.2009.01317.x
- Issue published online: 16 MAR 2010
- Article first published online: 6 JAN 2010
- Received 24 June 2009, revised and accepted for publication 21 September 2009
- CGG repeat;
- fragile X syndrome;
Hunter JE, Rohr JK, Sherman SL. Co-occurring diagnoses among FMR1 premutation allele carriers.
Following the discovery of two disorders associated with premutation alleles of the fragile X mental retardation gene (FMR1), primary ovarian insufficiency [fragile X-associated primary ovarian insufficiency (FXPOI)] and a tremor/ataxia syndrome [fragile X-associated tremor/ataxia disorder (FXTAS)], numerous studies have examined other potential co-morbid conditions, including neuropsychological deficits. Here, the frequency of self-reported diagnoses obtained through medical history interviews from FMR1 premutation carriers and non-carriers aged 18–50 were analyzed. Study subjects included 537 women, 334 of whom carry the premutation and 151 men, 37 of whom carry the premutation. Men with the premutation did not report any medical conditions at higher rates compared with non-carriers, controlling for age, ethnicity/race, and household income. Women with the premutation reported mental health disorders [i.e. attention deficit hyperactivity disorder (ADHD), anxiety, depression] significantly more often than non-carriers. However, after adjusting for covariates, these increased rates were not statistically significant. Additional follow-up analyses examined the consequence of ovarian dysfunction as a cause of co-occurring conditions. Women with an indication of ovarian insufficiency (i.e. irregular cycles) reported higher rates of thyroid problems and depression/anxiety. Because only women, not men, reported these conditions more often, the relationship between FXPOI and hormone irregularities in women should be explored for a potential link with the increase in the reported medical conditions.